Pharmacokinetics and Pharmacodynamics Practice Questions

Q: The ratio of the median lethal dose to the median effective dose is the:

Therapeutic index. **Explanation:** The **Therapeutic Index (TI)** is a quantitative measurement of the relative safety of a drug. It is defined as the ratio of the dose that produces toxicity in 50% of the population (**Median Lethal Dose or $LD_{50}$**) to the dose that produces the desired clinical effect in 50% of the population (**Median Effective Dose or $ED_{50}$**). $$\text{Therapeutic Index} = \frac{LD_{50}}{ED_{50}}$$ A higher TI indicates a wider margin of safety, meaning a much larger dose is required to cause death than to achieve a cure. **Analysis of Incorrect Options:** * **Morbidity and Mortality Indices:** These are epidemiological terms used to measure the frequency of disease and death within a population, respectively; they are not used to describe drug dosage ratios. * **Anesthetic Ratio:** While related to the safety margin of anesthetic agents, it is not the standard pharmacological term for the $LD_{50}/ED_{50}$ ratio. **High-Yield Clinical Pearls for NEET-PG:** * **Narrow Therapeutic Index (NTI) Drugs:** These drugs require frequent **Therapeutic Drug Monitoring (TDM)** because small increments in dose can lead to severe toxicity. Mnemonic: **"WATT"** (**W**arfarin, **A**minoglycosides/Amphotericin B, **T**heophylline, **T**ricyclic Antidepressants) + **Lithium, Digoxin, and Phenytoin.** * **Certainty Safety Factor:** Since $LD_{50}$ and $ED_{50}$ only look at the 50% mark, the "Standard Safety Margin" ($LD_1/ED_{99}$) is often considered a more clinically relevant measure of safety. * **Penicillin** has a very high therapeutic index, while **Digoxin** has a very low (narrow) therapeutic index.

Q: True regarding the following is?

C is least potent.. ***C is least potent*** - **Potency** is determined by the **EC50 value** - the dose required to produce 50% of the maximum response; **curve C** is positioned furthest to the right, indicating the **highest EC50** and therefore the **least potency**. - In dose-response curves, **rightward shift** indicates decreased potency, meaning higher doses are needed to achieve the same effect. *A has the highest efficacy* - **Efficacy** refers to the **maximum response (Emax)** achievable, represented by the **height** of the dose-response curve, not the horizontal position. - All curves appear to reach similar maximum heights, so **curve A does not have superior efficacy** compared to others. *A has the least potency* - **Curve A** is positioned furthest to the **left**, indicating the **lowest EC50** and therefore the **highest potency**, not the least. - **Leftward position** on dose-response curves indicates **greater potency**, requiring lower doses to achieve effects. *D has the highest potency* - **Curve D** is not positioned furthest to the left; **curve A** appears to have the **leftmost position** indicating the highest potency. - **Potency ranking** from highest to lowest appears to be: **A > B > D > C** based on their horizontal positions.

Q: All of the following drugs act on ionic channels except?

Insulin. ### Explanation The correct answer is **Insulin (Option B)**. To answer this question, one must distinguish between the four major types of drug receptors: Ion channels, G-protein coupled receptors (GPCRs), Enzyme-linked receptors, and Intracellular receptors. **1. Why Insulin is the correct answer:** Insulin does not act on an ion channel. Instead, it binds to a **Tyrosine Kinase Receptor**, which is a type of **Enzyme-linked receptor**. Upon insulin binding, the intracellular domain of the receptor undergoes autophosphorylation, triggering a signaling cascade (via IRS-1/2 and PI3K pathways) that leads to the translocation of GLUT-4 transporters to the cell membrane. **2. Analysis of incorrect options:** * **Nicotine (Option A):** Acts on **Nicotinic Acetylcholine Receptors (nAChR)**, which are classic examples of **Ligand-gated ion channels** (ionotropic receptors). Binding allows the influx of sodium ($Na^+$) and potassium ($K^+$) ions. * **Glibenclamide (Option C):** This Sulfonylurea acts on the **ATP-sensitive Potassium ($K_{ATP}$) channels** in pancreatic beta cells. By closing these channels, it causes depolarization, leading to insulin release. * **Diazepam (Option D):** A Benzodiazepine that acts as a positive allosteric modulator of the **$GABA_A$ receptor**, which is a **Ligand-gated Chloride ($Cl^-$) channel**. **High-Yield Clinical Pearls for NEET-PG:** * **Fastest acting receptors:** Ligand-gated ion channels (milliseconds). * **Slowest acting receptors:** Nuclear/Intracellular receptors (hours to days). * **Enzyme-linked receptors:** Besides Insulin, Growth Factors (EGF, PDGF) and ANP also utilize this class. * **$K_{ATP}$ Channel:** Targeted by both Sulfonylureas (blockers) and Minoxidil/Diazoxide (openers).

Q: Which of the following drugs does NOT have high hepatic clearance?

Paracetamol. ### Explanation The concept of **Hepatic Clearance** depends on the **Extraction Ratio (ER)**. Drugs with a high ER (>0.7) are cleared rapidly by the liver, meaning their clearance is limited by hepatic blood flow (Flow-dependent clearance). Drugs with a low ER (<0.3) are cleared slowly, and their clearance depends on the metabolic capacity of enzymes (Capacity-limited clearance). **1. Why Paracetamol is the correct answer:** Paracetamol has a **low hepatic extraction ratio**. While it is primarily metabolized by the liver (glucuronidation and sulfation), the process is relatively slow compared to hepatic blood flow. Therefore, it does not undergo extensive first-pass metabolism to the same degree as high-ER drugs, and its systemic bioavailability is high (approx. 70-90%). **2. Why the other options are incorrect:** * **Labetalol:** This is a classic example of a drug with a **high extraction ratio**. It undergoes significant first-pass metabolism, leading to lower oral bioavailability. * **Simvastatin:** This is a prodrug with very high hepatic extraction. It is specifically taken up by the liver (its target organ) during the first pass, resulting in less than 5% systemic bioavailability. * **Morphine:** Morphine undergoes extensive first-pass metabolism (primarily glucuronidation), giving it a high hepatic clearance. This is why the oral dose of morphine must be significantly higher than the parenteral dose to achieve the same effect. **Clinical Pearls for NEET-PG:** * **High ER Drugs (Mnemonic: "LIVS"):** **L**idocaine, **I**sosorbide dinitrate, **V**erapamil, **S**albutamol. Also includes Propranolol, Nitroglycerin, and Pethidine. * **Flow-dependent clearance:** For high ER drugs, any condition that decreases hepatic blood flow (e.g., Congestive Heart Failure, Propranolol) will decrease their clearance. * **Bioavailability:** Drugs with high hepatic clearance always have low oral bioavailability.

Q: The mechanism of action of protamine, an antidote for heparin, is based on which of the following?

Chemical antagonism. **Explanation:** **1. Why Chemical Antagonism is Correct:** Chemical antagonism occurs when two substances combine in solution, resulting in the chemical neutralization of the drug's effect without involving a specific biological receptor. **Heparin** is a highly acidic, negatively charged molecule (polyanion). **Protamine sulfate** is a strongly basic, positively charged protein (polycation). When administered, protamine binds ionically to heparin to form a stable, inactive **salt complex**. This direct chemical interaction neutralizes heparin’s anticoagulant activity, making it a classic example of chemical antagonism. **2. Why Other Options are Incorrect:** * **A. Competitive Antagonism:** This involves two drugs competing for the same receptor site (e.g., Atropine vs. Acetylcholine at muscarinic receptors). Protamine does not bind to the antithrombin III receptor site; it binds to the drug itself. * **C. Non-competitive Antagonism:** This occurs when an antagonist binds to an allosteric site or irreversibly to the receptor, preventing the agonist from producing a maximal effect. Again, this requires a receptor-mediated mechanism, which is absent here. * **D. Toxic Reaction:** While protamine can have side effects (like hypotension or anaphylaxis), its primary therapeutic mechanism is neutralization, not toxicity. **3. NEET-PG High-Yield Clinical Pearls:** * **Dosage:** 1 mg of protamine neutralizes approximately 100 units of heparin. * **Source:** Protamine is derived from **salmon sperm**; patients with fish allergies or those who have had vasectomies (due to anti-sperm antibodies) are at higher risk of hypersensitivity. * **Paradoxical Effect:** Excessive doses of protamine can actually exert an anticoagulant effect by inhibiting platelets and clotting factors. * **Other Examples of Chemical Antagonism:** Chelating agents (like Dimercaprol for heavy metals) and antacids neutralizing gastric acid.

Q: Which of the following is NOT an example of a Phase II drug metabolic reaction?

Decyclization. Drug metabolism (biotransformation) occurs in two distinct phases to make lipophilic drugs more water-soluble for excretion. **Explanation of the Correct Answer:** **Decyclization** is a **Phase I reaction**. Phase I reactions (Nonsynthetic) involve the introduction or unmasking of a functional group through oxidation, reduction, or hydrolysis. Decyclization specifically refers to the opening of a ring structure (e.g., the metabolism of barbiturates). Other Phase I reactions include Oxidation (most common, via CYP450), Reduction, Hydrolysis, and Cyclization. **Explanation of Incorrect Options:** Phase II reactions (Synthetic/Conjugation) involve attaching an endogenous moiety to the drug to form a highly polar, inactive metabolite. * **A. Acetylation:** A Phase II reaction catalyzed by N-acetyltransferase (NAT). Common examples include Sulfonamides, Isoniazid, and Hydralazine. * **B. Sulfation:** A Phase II reaction where a sulfate group is added (e.g., for Paracetamol or Steroids). * **D. Methylation:** A Phase II reaction involving the addition of a methyl group (e.g., for Adrenaline or Histamine). **High-Yield NEET-PG Pearls:** * **Glucuronidation** is the most common Phase II reaction. * **Microsomal vs. Non-microsomal:** Most Phase I and Glucuronidation enzymes are microsomal (located in the SER). Other Phase II reactions (Acetylation, Sulfation) are primarily **non-microsomal (cytosolic)**. * **Pharmacogenetics:** Acetylation shows genetic polymorphism (Fast vs. Slow acetylators), which is clinically significant for drugs like Isoniazid (risk of peripheral neuropathy in slow acetylators). * **Exception:** While Phase II usually inactivates drugs, **Morphine-6-glucuronide** is a rare example of a Phase II metabolite that is more active than the parent drug.

Q: Which of the following pairs represent physiological antagonists?

Glucagon and Insulin. **Explanation:** **Physiological antagonism** (also known as functional antagonism) occurs when two drugs act on **different receptors** and through **different mechanisms**, but produce **opposite effects** on the same physiological system [1]. **1. Why Glucagon and Insulin is correct:** Glucagon and Insulin act on distinct receptors (Glucagon receptors vs. Insulin tyrosine kinase receptors). However, they exert opposing effects on blood glucose levels: Insulin causes hypoglycemia, while Glucagon causes hyperglycemia [2]. Because they cancel each other's functional effects via different pathways, they are classic physiological antagonists [1]. **2. Why the other options are incorrect:** * **Adrenaline and Isoprenaline (Option A):** Both are adrenergic agonists. They act on similar receptors ($\beta$-receptors) to produce synergistic (additive) effects, not antagonistic ones. * **Isoprenaline and Propranolol (Option C):** This is an example of **Pharmacological (Receptor) Antagonism**. Propranolol is a $eta$-blocker that competes with Isoprenaline for the same $eta$-receptor site [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Classic Example:** The most frequently asked example of physiological antagonism is **Adrenaline and Histamine** on bronchial smooth muscle (Adrenaline causes bronchodilation via $eta_2$ receptors; Histamine causes bronchoconstriction via $H_1$ receptors). * **Chemical Antagonism:** Occurs when two drugs react chemically to form an inactive product (e.g., Chelating agents like EDTA for lead poisoning, or Protamine sulfate for Heparin overdose). * **Pharmacokinetic Antagonism:** One drug reduces the concentration of another by interfering with its absorption, metabolism (e.g., Enzyme inducers like Rifampicin), or excretion.

Q: Which route of drug administration avoids first-pass hepatic metabolism and is used for drug preparations that slowly release drugs for periods as long as seven days?

Transdermal. **Explanation** The correct answer is **Transdermal (Option B)**. **Why Transdermal is Correct:** The transdermal route involves the application of a drug to the skin (usually via a patch) for systemic absorption. It bypasses the gastrointestinal tract and the portal circulation, thereby **avoiding first-pass hepatic metabolism**. A key characteristic of transdermal delivery systems (TDS) is their ability to provide a **controlled, sustained release** of medication. This maintains steady-state plasma concentrations for extended periods, ranging from 24 hours to as long as **seven days** (e.g., Scopolamine or Clonidine patches). **Why Other Options are Incorrect:** * **Topical (A):** While applied to the skin, topical administration is intended for **local effect** (e.g., clotrimazole cream for fungal infections) rather than systemic absorption. * **Sublingual (C):** This route bypasses first-pass metabolism by absorbing drugs directly into the systemic circulation via the sublingual mucosa. However, it is used for **rapid onset** of action (e.g., Nitroglycerin for angina) and cannot provide sustained release for several days. * **Oral (D):** This is the most common route but is subject to significant **first-pass metabolism** in the liver and gut wall. It generally requires frequent dosing compared to long-acting patches. **NEET-PG High-Yield Pearls:** * **Drugs given via Transdermal Patch:** Nitroglycerin, Fentanyl (3 days), Nicotine, Hyoscine (3 days), Granisetron (7 days), and Hormonal contraceptives. * **Ideal Drug Properties for Transdermal Route:** Low molecular weight (<500 Da), high lipid solubility, and high potency (effective at low doses). * **Pro-tip:** The rate-controlling step in transdermal absorption is typically the **stratum corneum** of the epidermis.

Question 1

The ratio of the median lethal dose to the median effective dose is the:

Accepted Answer

Therapeutic index

Answer

Morbidity index

Answer

Mortality index

Answer

Anesthetic ratio

Question 2

True regarding the following is?

Accepted Answer

C is least potent.

Answer

A has the highest efficacy.

Answer

A has the least potency.

Answer

D has the highest potency.

Question 3

Regarding phenytoin, all are true except?

Accepted Answer

At lower concentration, it follows zero-order kinetics

Answer

Potent microsomal enzyme inducer

Answer

Highly protein bound

Answer

With increasing dose, the half-life increases

Question 4

All of the following drugs act on ionic channels except?

Accepted Answer

Insulin

Answer

Nicotine

Answer

Glibenclamide

Answer

Diazepam

Question 5

Bioavailability is defined as:

Accepted Answer

The fraction of an administered dose of unchanged drug that reaches the systemic circulation

Answer

The extent of drug metabolism in the liver before reaching the systemic circulation

Answer

The extent of drug metabolism in the liver after reaching the systemic circulation

Answer

The fraction of a dose administered via the rectal route that reaches the systemic circulation

Question 6

Which of the following drugs does NOT have high hepatic clearance?

Accepted Answer

Paracetamol

Answer

Labetalol

Answer

Simvastatin

Answer

Morphine

Question 7

The mechanism of action of protamine, an antidote for heparin, is based on which of the following?

Accepted Answer

Chemical antagonism

Answer

Competitive antagonism

Answer

Non-competitive antagonism

Answer

Toxic reaction

Question 8

Which of the following is NOT an example of a Phase II drug metabolic reaction?

Accepted Answer

Decyclization

Answer

Acetylation

Answer

Sulfation

Answer

Methylation

Question 9

Which of the following pairs represent physiological antagonists?

Accepted Answer

Glucagon and Insulin

Answer

Adrenaline and Isoprenaline

Answer

Isoprenaline and Propranolol

Answer

All of the above

Question 10

Which route of drug administration avoids first-pass hepatic metabolism and is used for drug preparations that slowly release drugs for periods as long as seven days?

Accepted Answer

Transdermal

Answer

Topical

Answer

Sublingual

Answer

Oral

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?